Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2025 results on April 29, 2025. The Zacks ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Swiss drugmaker Novartis said today it plans to spend $23 billion to build and expand 10 facilities in the US, as it grapples with renewed threats of drug import duties from the Trump administration.

Swiss pharmaceutical giant Novartis announced Thursday that it plans to expand its manufacturing and research and development activities in the US with an investment of $23 billion over the next ...

SAN DIEGO — Novartis, a Swiss pharmaceutical company, announced a planned $23 billion investment over the next five years aimed at expanding its U.S.-based infrastructure. The move ensures that ...

Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities. The move comes after President Trump earlier this week threatened "major" tariffs on ...

Pharmaceutical company Novartis said it plans to expand U.S.-based manufacturing and research and development, with a total investment of $23 billion over the next five years. The company said it ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Viking Therapeutics has multiple promising drugs in its portfolio that could generate billions in future revenue. Approval of VK2735 and VK2809 could lead to a surge in the stock's value.

According to the company, the strategic move aims to establish PharmaLogic as the first fully integrated, global CDMO focused exclusively on radiopharmaceutical therapeutics. Under the terms of the ...

Get the next trade alert free. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients ...